IVVD stock forecast, quote, news & analysis
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases... Show more
Invivyd (IVVD) Stock Analysis: Pipeline Momentum Meets Revenue Growth
Key Takeaways
- Invivyd reported preliminary Q4 2025 PEMGARDA net product revenue of $17.2 million, up 25% year-over-year and 31% quarter-over-quarter.
- FDA alignment on the LIBERTY Phase 3 trial for VYD2311 advances the company's next-generation COVID antibody candidate, with topline data expected mid-2026.
- Analysts maintain a consensus "Hold" to "Buy" rating with an average price target of $8.00, implying substantial upside from current levels.
- Strong cash position of approximately $227 million supports ongoing clinical trials and commercialization efforts.
- Recent partnership with Lindsey Vonn highlights efforts to raise awareness of antibody prophylaxis amid declining vaccination trends.
Current Market Snapshot
Invivyd (IVVD) stock has navigated volatile trading in recent weeks, reflecting biotech sector dynamics and company-specific catalysts. Shares have fluctuated within a 52-week range of $0.46 to $3.07, with heightened volume accompanying pipeline advancements and revenue updates. The stock's year-to-date gain of over 30% underscores investor interest in PEMGARDA's commercial traction and the promise of VYD2311, even as broader market pressures on small-cap biotechs weigh on sentiment. Market capitalization hovers around $460 million, positioning IVVD as a speculative play in the infectious disease space.
Recent Developments Driving IVVD Price Action
Invivyd's stock price has been influenced by a series of clinical, commercial, and financial milestones over the past 30 days, blending positive momentum with biotech volatility. On January 8, 2026, the company disclosed preliminary fourth-quarter 2025 net product revenue from PEMGARDA (pemivibart), its FDA-authorized monoclonal antibody for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals, at $17.2 million. This marked a 25% increase from Q4 2024's $13.8 million and 31% sequential growth from Q3 2025's $13.1 million, signaling robust demand despite waning overall COVID vaccination rates. Management attributed the uptick to effective commercial execution and the antibody's appeal as a vaccine alternative. Ending cash stood at $226.7 million, bolstered by over $200 million raised in the second half of 2025, providing runway for pipeline expansion.
Pipeline progress dominated headlines on February 3, 2026, when Invivyd announced FDA alignment on the LIBERTY Phase 3 trial design for VYD2311, its next-generation half-life extended antibody. The study will compare VYD2311's safety against mRNA COVID vaccines and assess co-administration, part of the broader REVOLUTION program. Shares rose on the news, reflecting de-risking of the candidate, which previously earned Fast Track designation in December 2025. Earlier, on January 20, the company revealed plans with the SPEAR Study Group for a Phase 2 trial of VYD2311 targeting Long COVID and COVID vaccine-injured patients, set to start mid-2026. These updates drove intraday gains but faced profit-taking amid sector rotation.
Strategic visibility efforts included a January 22 partnership with Olympic skier Lindsey Vonn to educate on antibodies and disease prevention, boosting shares temporarily as it tapped into public health awareness. Analyst sentiment remained supportive, with BTIG initiating Buy coverage in late December 2025 at $10, HC Wainwright raising its target to $10, and consensus around $8 amid "Hold" to "Buy" ratings. However, price action showed pullbacks, including a 26% drop noted in late January, linked to profit-taking post-rallies and broader biotech weakness. Trading volume spiked to multi-million shares on news days, amplifying swings, while the stock's low float contributed to volatility. Overall, these developments linked revenue validation and regulatory tailwinds to intermittent upside, tempered by execution risks in a maturing COVID market.
2026 Outlook and Key Factors to Monitor
As Invivyd advances through 2026, focus will center on VYD2311's clinical trajectory, including topline data from the DECLARATION Phase 3 trial mid-year and the LIBERTY study's progress. Success here could validate the company's INVYMAB platform for serial antibody generation against evolving viral threats, potentially expanding beyond COVID to RSV (VBY329 preclinical) and measles candidates. PEMGARDA's commercialization remains pivotal, with sustained revenue growth critical amid shifting epidemiology and competition from vaccines.
Investors should track gross margins (previously 93%), cash burn rates against the $227 million runway, and full-year 2026 revenue consensus around $128 million, with EPS estimates improving toward breakeven. Regulatory milestones, such as full BLA submissions or expanded indications, alongside the Phase 2 Long COVID study, offer catalysts. Risks include variant escape, trial setbacks, or reimbursement hurdles, while opportunities lie in partnerships and platform diversification. Macro factors like infectious disease funding and biotech M&A sentiment will also shape positioning.
IVVD's RSI Oscillator ascends from oversold territory
The RSI Oscillator for IVVD moved out of oversold territory on June 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 45 similar instances when the indicator left oversold territory. In of the 45 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 56 cases where IVVD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IVVD just turned positive on June 18, 2026. Looking at past instances where IVVD's MACD turned positive, the stock continued to rise in of 36 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IVVD advanced for three days, in of 227 cases, the price rose further within the following month. The odds of a continued upward trend are .
IVVD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IVVD as a result. In of 72 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVVD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for IVVD entered a downward trend on June 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.329) is normal, around the industry mean (20.966). P/E Ratio (0.000) is within average values for comparable stocks, (36.007). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). IVVD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (3.601) is also within normal values, averaging (367.026).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IVVD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVVD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology